Contributions
Abstract: EP1736
Type: Poster Sessions
Abstract Category: Therapy - Others
Background: In the desmyelinating diseases the remyelination its a target. During attacks in the Multiple Sclerosis, methyl-prednisolone is the treatment of first choice, and there is controversy about the effect of prednisolone on generation of OPC and remyelination.
Objectives: To analyze if methylprednisolone affects the expression of oligodendroglial maturation and proliferation markers in vitro
Methods: Mouse neurospheres and HOG line cells were cultured for 3, 5, 7, 10 and 15 days in the presence of different doses of methyl prednisolone (0.5, 2, 5, 10, 30 and 50 µM), we analyzed the clonal capacity, and expression by immunocytochemical of caspase 3 (as a marker of death), Ki67 (Cell proliferation) and different stages of oligodendroglial maturation (NG2, Olig2, Oligodendrocytes, CNPase and MBP / PLP).
Results: Methyl prednisolone affects the proliferation and differentiation of oligodendrocytes significantly at all times and under all doses analyzed. In addition to a higher concentration of methylprednisolone shows greater cytotoxicity and affects the expression of oligodendroglial markers.
Conclusions: Our results suggest that methyl prednisolone affects the proliferation, differentiation and maturation of oligodendrocytes. Therefore, its use as a first-choice treatment in multiple sclerosis can have a negative connotation if remyelination is target.
Key words: Neurospheres, oligodendrocytes, remyelination, Corticoids, Methyl prednisolone, Multiple Sclerosis
Disclosure: Ulises Gómez-Pinedo: nothing to disclose
Paloma Montero Escribano: nothing to disclose
Vanesa Pytel: nothing to disclose
Lidia Moreno-Jiménez: nothing to disclose
Maria Soledad Benito-Martín: nothing to disclose
Laura Torre-Fuentes: nothing to disclose
Noelia Esteban Garcia: nothing to disclose
Jordi A. Matias-Guiu: nothing to disclose
Jorge Matias-Guiu: nothing to disclose
Abstract: EP1736
Type: Poster Sessions
Abstract Category: Therapy - Others
Background: In the desmyelinating diseases the remyelination its a target. During attacks in the Multiple Sclerosis, methyl-prednisolone is the treatment of first choice, and there is controversy about the effect of prednisolone on generation of OPC and remyelination.
Objectives: To analyze if methylprednisolone affects the expression of oligodendroglial maturation and proliferation markers in vitro
Methods: Mouse neurospheres and HOG line cells were cultured for 3, 5, 7, 10 and 15 days in the presence of different doses of methyl prednisolone (0.5, 2, 5, 10, 30 and 50 µM), we analyzed the clonal capacity, and expression by immunocytochemical of caspase 3 (as a marker of death), Ki67 (Cell proliferation) and different stages of oligodendroglial maturation (NG2, Olig2, Oligodendrocytes, CNPase and MBP / PLP).
Results: Methyl prednisolone affects the proliferation and differentiation of oligodendrocytes significantly at all times and under all doses analyzed. In addition to a higher concentration of methylprednisolone shows greater cytotoxicity and affects the expression of oligodendroglial markers.
Conclusions: Our results suggest that methyl prednisolone affects the proliferation, differentiation and maturation of oligodendrocytes. Therefore, its use as a first-choice treatment in multiple sclerosis can have a negative connotation if remyelination is target.
Key words: Neurospheres, oligodendrocytes, remyelination, Corticoids, Methyl prednisolone, Multiple Sclerosis
Disclosure: Ulises Gómez-Pinedo: nothing to disclose
Paloma Montero Escribano: nothing to disclose
Vanesa Pytel: nothing to disclose
Lidia Moreno-Jiménez: nothing to disclose
Maria Soledad Benito-Martín: nothing to disclose
Laura Torre-Fuentes: nothing to disclose
Noelia Esteban Garcia: nothing to disclose
Jordi A. Matias-Guiu: nothing to disclose
Jorge Matias-Guiu: nothing to disclose